Prostate cancer is one of the most common cancers affecting men worldwide. However, planning personalized radiotherapy in the ...
Clinicians report that early AKT inhibition side effects are manageable, allowing four out of five patients to maintain ...
Morning Overview on MSN
A targeted drug won approval for a hard-to-treat form of advanced prostate cancer
Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...
Immunotherapy: Hope, Hurdles, and a Clever Disguise Immunotherapies stand as one of the most promising paths in modern cancer treatment. Their main goal? To help the body’s own immune system hunt down ...
A new cancer drug may be able to inhibit both tumor growth and the spread of aggressive prostate cancer. This is shown in a ...
Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date - Dose-dependent anti-tumo ...
First patients dosed in OPTIMAL-e1 Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent’s Hospital ...
Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine ...
The metastatic castration-resistant prostate cancer market is poised for substantial growth over the coming years, driven by ...
The Ellison Medical Institute (EMI) has entered into an exclusive license with UniQuest, the commercialization company of The University of Queensland (UQ), to advance QED-203, a promising new ...
REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2In ...
Doctors say prostate cancer cases are rising across smaller towns and neighbouring states, but delayed diagnosis continues to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results